IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro

IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro

The ongoing pandemic spread of the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) demands skillful strategies for novel drug development, drug repurposing and cotreatments, in particular focusing on existing candidates of host-directed antivirals (HDAs). The developmental drug IMU...

Full description

Bibliographic Details
Main Authors: Friedrich Hahn, Christina Wangen, Sigrun Häge, Antonia Sophia Peter, Gerhard Dobler, Brett Hurst, Justin Julander, Jonas Fuchs, Zsolt Ruzsics, Klaus Überla, Hans-Martin Jäck, Roger Ptak, Andreas Muehler, Manfred Gröppel, Daniel Vitt, Evelyn Peelen, Hella Kohlhof, Manfred Marschall
Format: Article
Language:English
Published: MDPI AG 2020-12-01
Series:Viruses
Subjects:
SARS-CoV-2
antiviral therapy
host-directed antivirals (HDAs)
dihydroorotate dehydrogenase (DHODH) inhibitors
IMU-838
vidofludimus
Online Access:https://www.mdpi.com/1999-4915/12/12/1394

Internet

https://www.mdpi.com/1999-4915/12/12/1394

Similar Items